Data layers Raw facts Calculated Model prediction AI interpretation

IPO Timeline Raw facts

Broker Results (T-2)
Some brokers release in afternoon
Grey Market (T-1)
Afternoon
HKEX Allotment (T-1)
Evening
Registrar Allotment (T-1)
Evening
Listing Day (T)
First day of trading

Company Overview

Stock NameRimag Group
Stock Code02522
Company Full NameTo be extracted
Industry醫療保健
Principal Activities公司是中國一家領先的醫學影像專科醫療集團,為整個醫學影像產業鏈提供多元化影像服務及價值的醫學影像平臺運營商及管理者。
Listing Date2024-06-07
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國北京市朝陽區民族園路2號2幢
Business Address (Hong Kong)To be extracted
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitehttps://www.rimag.com.cn/
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo data

Offering Information

Offering Mechanism To be extracted
Offer PriceHK$ 14.98 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer PeriodTo be extracted
Global Offering SharesTo be extracted
HK Public Offer Shares (Initial)To be extracted
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)To be extracted
Offer RatioTo be extracted
Total Shares Post-IPOTo be extracted
Greenshoe (Over-allotment Option)To be confirmed
Stabilizing Manager (Greenshoe)—
Cornerstone Share45.0%
Clawback TiersTo be extracted
Reallocation OptionTo be confirmed
Total Global Offering SizeHK$ 133,441,840

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 500 HK$ 7,490
2 lots 1,000 HK$ 14,980
3 lots 1,500 HK$ 22,470
4 lots 2,000 HK$ 29,960
5 lots 2,500 HK$ 37,450
6 lots 3,000 HK$ 44,940
7 lots 3,500 HK$ 52,430
8 lots 4,000 HK$ 59,920
9 lots 4,500 HK$ 67,410
10 lots 5,000 HK$ 74,900
12 lots 6,000 HK$ 89,880
14 lots 7,000 HK$ 104,860
16 lots 8,000 HK$ 119,840
18 lots 9,000 HK$ 134,820
20 lots 10,000 HK$ 149,800
30 lots 15,000 HK$ 224,700
40 lots 20,000 HK$ 299,600
50 lots 25,000 HK$ 374,500
60 lots 30,000 HK$ 449,400
70 lots 35,000 HK$ 524,300
80 lots 40,000 HK$ 599,200
90 lots 45,000 HK$ 674,100
100 lots 50,000 HK$ 749,000
120 lots 60,000 HK$ 898,800
140 lots 70,000 HK$ 1,048,600
160 lots 80,000 HK$ 1,198,400
180 lots 90,000 HK$ 1,348,200
200 lots 100,000 HK$ 1,498,000
300 lots 150,000 HK$ 2,247,000
400 lots 200,000 HK$ 2,996,000
500 lots 250,000 HK$ 3,745,000
600 lots 300,000 HK$ 4,494,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
700 lots 350,000 HK$ 5,243,000
800 lots 400,000 HK$ 5,992,000
900 lots 450,000 HK$ 6,741,000
1,000 lots 500,000 HK$ 7,490,000
1,200 lots 600,000 HK$ 8,988,000
1,400 lots 700,000 HK$ 10,486,000
1,600 lots 800,000 HK$ 11,984,000
1,782 lots 891,000 HK$ 13,347,180

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway None
Avg Daily HK Mkt Cap ---
Est. Threshold ---
Analysis Result 无法确定入通路径

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss StatusTo be extracted
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted
First Day CloseHK$ 15.0
First Day OpenHK$ 15.0
First Day Change0.13%
First Day Volume12268300.0
First Day Turnover185911000.0
Use of Proceeds
1、約50.0%或111.9百萬港元,用于擴充醫學影像中心網絡; 2、約20.0%或44.8百萬港元,用于在醫學影像領域尋求戰略合作及并購的機會以及在醫療影像服務產業鏈中尋求戰略合作及投資機會; 3、約20.0%或44.8百萬港元,用于將業務拓展至(i)相對缺乏醫療資源的海外國家和地區;及(ii)人均可支配收入高以及在醫療影像服務方面具有龐大增長潛力的海外國家和地區; 4、約10.0%或22.4百萬港元,用作營運資金及一般公司用途。

Underwriting Syndicate

Sole Sponsor (1)
CITIC Securities (Hong Kong) Limited CE AAK249
Overall Coordinators (4)
CLSA LIMITED CE AAB893 招银国际融资有限公司 CE AVM940 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 Fosun International Securities Limited CE AAF432
Joint Bookrunners (15)
CLSA LIMITED CE AAB893 招银国际融资有限公司 CE AVM940 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 Fosun International Securities Limited CE AAF432 农银国际证券有限公司 CE ACX411 中国银河国际证券(香港)有限公司 CE AXM459 富途证券国际(香港)有限公司 CE AZT137 ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299 PATRONS SECURITIES LIMITED CE BPQ161 Quam Securities Limited CE AAC577 SPDB International Capital Limited CE BFZ375 TradeGo Markets Limited CE BRO637 Victoria Harbour International Financial Holdings Limited CE BRQ593 YUE XIU SECURITIES COMPANY LIMITED CE ABQ722 ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855
Joint Lead Managers (15)
CLSA LIMITED CE AAB893 招银国际融资有限公司 CE AVM940 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 Fosun International Securities Limited CE AAF432 农银国际证券有限公司 CE ACX411 中国银河国际证券(香港)有限公司 CE AXM459 富途证券国际(香港)有限公司 CE AZT137 ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299 PATRONS SECURITIES LIMITED CE BPQ161 Quam Securities Limited CE AAC577 SPDB International Capital Limited CE BFZ375 TradeGo Markets Limited CE BRO637 Victoria Harbour International Financial Holdings Limited CE BRQ593 YUE XIU SECURITIES COMPANY LIMITED CE ABQ722 ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 联影医疗科技香港有限公司 11,998,980 HKD — 4.50% — 6 months 2024-12-07
2 中国新锐医药控股有限公司 11,998,980 HKD — 4.50% — 6 months 2024-12-07
3 卓投企业管理(香港)有限公司 96,029,290 HKD — 35.98% — 6 months 2024-12-07

Directors & Management

PositionChinese nameEnglish Name
Chairman陳朝陽—
Company Secretary何英飛;張瀟—
No director data available.

Major Shareholders

Major Shareholders & Holdings南昌一脈陽光企業管理中心(有限合伙)(16.58%);王世和(4.98%);顧軍軍(4.98%)
AI AI Analysis AI interpretation deepseek-v4-pro · AI-generated
!
Underlying data failed quality checks; AI interpretation downgraded and shown for reference only.

Market Sentiment

The 336x oversubscription ratio reflects intense retail enthusiasm for this healthcare AI offering, likely bolstered by clawback reallocation that boosted the public tranche. A hit rate of 30.3% is relatively generous for such demand, allowing many small investors to obtain partial lots. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

Tier Analysis

A notable tier anomaly exists: the A-tail tier (250,000 shares) expects 0.6154 lots, nearly matching the B-head tier (300,000 shares, 0.7023 lots), indicating marginal allocation gain for a 20% larger application. This compression suggests poor broker fee efficiency for those barely entering margin financing, as the incremental capital yields minimal extra shares. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

Demographics

Mainland Chinese applicants comprised 78.3% of the holder base, signaling strong domestic demand and brand recognition for the company. The gender split is virtually even (49.8% male), and the average investor age of 46 points to a mature, experienced demographic. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

About this page

This page shows Rimag Group (02522) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect